#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives
Peter Attia discusses prostate cancer screening, explaining why advanced diagnoses are rising. He details modern tools like PSA velocity, MRI, and transperineal biopsies, advocating for regular testing to eliminate mortality, and warns about finasteride's effect on PSA.
Deep Dive Analysis
14 Topic Outline
Introduction to Prostate Cancer Screening and PSA
Rising Rates of Advanced Prostate Cancer
PSA Fundamentals and Early Screening Results
Harms of Early PSA Screening and Overtreatment
USPSTF Recommendations and PLCO Trial Flaws
Consequences of Reduced Screening: Worsening Outcomes
Modern Screening: PSA Velocity and Trends
MRI and PSA Density for Improved Detection
Advances in Prostate Biopsy: Transperineal Method
Reducing Overtreatment with Active Surveillance
Undermining USPSTF: PLCO Trial Contamination
Preventable Prostate Cancer Deaths: A Call to Action
Finasteride's Impact on PSA Interpretation
Optimistic Future for Prostate Cancer Mortality
8 Key Concepts
Prostate-Specific Antigen (PSA)
A protein produced by the prostate gland that helps keep seminal fluid liquid. A small amount naturally leaks into the bloodstream, and its level is measured in a blood test, tending to rise as the prostate grows or with malignancy.
PSA Velocity
The rate of change of PSA values over time, which is more informative than a single PSA snapshot. Rapid, sustained increases in PSA velocity can indicate pathological changes in the prostate, such as malignant growth.
PSA Density
The PSA concentration in the blood divided by the volume of the prostate, obtained via imaging like MRI. A disproportionate rise in PSA relative to prostate volume suggests a problem, as tumors can cause PSA to escape into the bloodstream more readily.
5-alpha-reductase Inhibitors
A class of drugs, including finasteride and dutasteride, that block the conversion of testosterone to dihydrotestosterone (DHT) in the prostate. This action significantly reduces PSA production, which can mask the presence of prostate cancer if PSA values are not correctly adjusted.
Over-diagnosis
The detection of cancers that would never have caused symptoms or threatened a person's life. This was a significant concern in early PSA screening, leading to unnecessary biopsies and treatments for indolent tumors.
Over-treatment
The administration of aggressive medical interventions (e.g., surgery, radiation) for cancers that are unlikely to progress or cause harm. This was a major drawback of early prostate cancer screening, leading to side effects like erectile dysfunction and incontinence without a clear survival benefit.
Active Surveillance
A management strategy for low-risk prostate cancers (e.g., Gleason Grade Group 1 or 2) where the cancer is carefully monitored over time instead of immediate treatment. This approach aims to delay or avoid treatment until it is truly necessary, reducing the burden of side effects.
Gleason Score/Grade Group
A grading system used by pathologists to assess the aggressiveness of prostate cancer cells from a biopsy. It assigns two numbers (e.g., 3+3, 4+3) based on cell abnormality, which are then compressed into a Grade Group (1-5), with higher numbers indicating more aggressive tumors.
7 Questions Answered
Advanced diagnoses are rising because current guidelines led to a pullback on PSA screening, causing cancers to be detected only after they have already metastasized and become incurable.
PSA (prostate-specific antigen) is a protein made by the prostate gland, and a small amount leaks into the bloodstream. Its measurement indicates prostate health, with elevated levels potentially signaling prostate growth or cancer.
Modern screening uses PSA as a longitudinal trend (velocity), incorporates MRI for better imaging and PSA density calculation, and employs safer transperineal biopsies, dramatically improving accuracy and reducing unnecessary procedures.
Finasteride suppresses PSA production, effectively cutting PSA values in half or more. This suppression can mask the presence of prostate cancer, requiring PSA values to be doubled or adjusted for correct interpretation.
Yes, for low-grade cancers (Gleason Grade Group 1 or 2), active surveillance protocols allow for careful monitoring with additional markers, ensuring timely treatment only if the cancer progresses, thereby avoiding overtreatment.
Early guidelines led to too many false alarms, invasive biopsies with infection risks, and overtreatment of indolent cancers that would never have threatened a man's life, causing significant side effects.
The PLCO trial, which concluded PSA screening was ineffective, was severely contaminated because a significant portion of the 'no screening' control group was actually undergoing PSA screening, making the comparison invalid.
9 Actionable Insights
1. Advocate for Regular PSA Testing
Actively seek regular Prostate-Specific Antigen (PSA) testing, as current guidelines have led to a measurable increase in incurable prostate cancers. Early detection with modern tools is crucial for preventing mortality.
2. Track PSA as a Trend
Do not rely on a single PSA reading; instead, track your PSA values over time to determine your PSA velocity. Rapid, sustained increases are a red flag for pathological changes, such as a rise of more than 0.35 ng/mL/year over 18 months for a baseline PSA less than 4 ng/mL.
3. Inform Doctors About Finasteride
If you are taking finasteride or dutasteride, ensure all your doctors, especially those interpreting PSA results, are aware. These drugs suppress PSA levels, and failure to account for this can mask prostate cancer.
4. Adjust PSA for Finasteride Use
If on finasteride for a year or longer, your raw PSA value needs to be at least doubled for correct interpretation. The correction factor may increase with duration, for example, multiplying by 2.3 after two to seven years on the drug and 2.5 beyond seven years.
5. Treat Any PSA Rise on Finasteride Seriously
If you are on long-term finasteride, your PSA should not rise; it may even decrease. Any upward movement in PSA should be treated as a serious warning sign and investigated, as it likely indicates a problem.
6. Consider MRI for Elevated PSA
If your PSA velocity indicates a concern, the next step should be an MRI, which is a non-invasive, high-resolution test. Request a contrast-free bi-parametric MRI, as it is equally effective, faster, and less costly than a full multi-parametric MRI.
7. Understand PSA Density
Use PSA density, which is your PSA concentration divided by prostate volume, as an additional diagnostic metric. If PSA is rising disproportionately to prostate volume, it strongly indicates something is wrong before a biopsy is needed.
8. Opt for Transperineal Biopsy
If a biopsy is warranted, choose a transperineal approach over the traditional transrectal method. This method dramatically reduces infection risk and provides better access to the prostate for more accurate detection of high-grade cancers.
9. Discuss Active Surveillance for Low-Risk Cancer
If diagnosed with low-grade prostate cancer (Gleason Grade Group 1 or 2), discuss active surveillance with your urologist. This approach allows for careful monitoring to avoid immediate, potentially unnecessary treatment and its associated side effects.
8 Key Quotes
Prostate cancer is the second leading cause of cancer death in men, with only lung cancer claiming more lives.
Peter Attia
What makes this disease both uniquely hopeful and uniquely frustrating is that when you catch it early, the prognosis is outstanding.
Peter Attia
The timing of when you find the cancer is not a minor detail. It's arguably the determining factor in life and death.
Peter Attia
We stopped looking for early disease so we started finding it late.
Peter Attia
The single biggest conceptual shift is this: PSA is most value as a longitudinal trend, not a single snapshot.
Peter Attia
The bottom line is this was a study comparing PSA screening to PSA screening and then concluding that screening doesn't work when they didn't find a difference.
Peter Attia
This isn't a cruelty of biology. It's a failure of our implementation.
Peter Attia
Finasteride does not appear to increase your actual risk of developing prostate cancer, but it can absolutely prevent your doctors from catching it on time.
Peter Attia
1 Protocols
Modern Prostate Cancer Screening and Management
Peter Attia- Regularly track Prostate-Specific Antigen (PSA) values over time to determine PSA velocity.
- If PSA velocity shows a sustained rapid increase (e.g., >0.35 ng/mL/year over 18 months for baseline <4 ng/mL), proceed to an MRI.
- Utilize MRI to identify suspicious lesions, calculate PSA density, and guide further action.
- If MRI flags a suspicious area, perform a transperineal biopsy to obtain tissue for diagnosis.
- For low-grade cancers (Gleason Grade Group 1 or 2), consider active surveillance with ongoing monitoring.
- For high-grade cancers (Gleason Grade Group 3, 4, or 5), pursue immediate treatment.